Paper21189395
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.
Press MF and 19 others. J Clin Oncol, 2011. Cited by 172 papers, by iCite.
Cite this record
ConductScience Library. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. Papers, record 21189395. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21189395
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.
- PubMed
- Publication types
Clinical Trial, Phase III, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.
- PubMed
Topics24
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anthracyclines | Major topic |
| Antigens, Neoplasm | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Breast Neoplasms | Major topic |
| DNA Topoisomerases, Type II | Major topic |
| DNA-Binding Proteins | Major topic |
| Gene Amplification | Major topic |
| Genes, erbB-2 | Major topic |
| Adult | |
| Aged | |
| Disease-Free Survival | |
| Female | |
| Gene Expression Regulation, Neoplastic | |
| Genetic Predisposition to Disease | |
| Humans | |
| In Situ Hybridization, Fluorescence | |
| Middle Aged | |
| Poly-ADP-Ribose Binding Proteins | |
| Prognosis | |
| Proportional Hazards Models | |
| Risk Assessment | |
| Statistics, Nonparametric | |
| Survival Analysis | |
| Treatment Outcome |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 CA048780 | NCI NIH HHS | United States | R01CA048780 | PubMed and NIH | NIH RePORTER |
| R01 CA077398 | NCI NIH HHS | United States | R01CA077398 | PubMed and NIH | NIH RePORTER |
| CA48780 | NCI NIH HHS | United States | R01CA048780 | PubMed and NIH | NIH RePORTER |
| CA77398 | NCI NIH HHS | United States | R01CA077398 | PubMed and NIH | NIH RePORTER |
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT00021255 | Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer | Background | ClinicalTrials.gov | |
| NCT04403984 | Investigation of Genomic Alteration in Patients With Luminal A or Luminal B Subtypes | Background | ClinicalTrials.gov |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 21670460 | Does topoisomerase II-alpha gene amplification provide useful information for treatment selection in patients with breast carcinoma? | https://conductscience.org/library/papers/21670460 |
Source PubMed
References62
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20079691 | Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). | Lancet Oncol | 2010 | https://conductscience.org/library/papers/20079691 | PubMed |
| 2 | 16234514 | retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. | J Clin Oncol | 2005 | https://conductscience.org/library/papers/16234514 | PubMed |
| 3 | 11121461 | HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. | J Natl Cancer Inst | 2000 | https://conductscience.org/library/papers/11121461 | PubMed |
| 4 | 16258081 | Trastuzumab cardiac side effects: only time will tell. | J Clin Oncol | 2005 | https://conductscience.org/library/papers/16258081 | PubMed |
| 5 | 20038724 | HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20038724 | PubMed |
| 6 | 15994142 | Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. | J Clin Oncol | 2005 | https://conductscience.org/library/papers/15994142 | PubMed |
| 7 | 14632727 | Topoisomerase IIalpha gene (TOP2A) amplification and deletion in cancer--more common than anticipated. | Cytopathology | 2003 | https://conductscience.org/library/papers/14632727 | PubMed |
| 8 | 9747867 | erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. | J Natl Cancer Inst | 1998 | https://conductscience.org/library/papers/9747867 | PubMed |
| 9 | 12755489 | HER-2/neu and topoisomerase IIalpha in breast cancer. | Breast Cancer Res Treat | 2003 | https://conductscience.org/library/papers/12755489 | PubMed |
| 10 | 16137437 | HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results. | Clin Breast Cancer | 2005 | https://conductscience.org/library/papers/16137437 | PubMed |
| 11 | 12560435 | HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer. | J Clin Oncol | 2003 | https://conductscience.org/library/papers/12560435 | PubMed |
| 12 | 12118023 | Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. | J Clin Oncol | 2002 | https://conductscience.org/library/papers/12118023 | PubMed |
| 13 | 17284714 | Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. | J Natl Cancer Inst | 2007 | https://conductscience.org/library/papers/17284714 | PubMed |
| 14 | 12602919 | Comparison of topoisomerase-IIalpha gene status between primary breast cancer and corresponding distant metastatic sites. | Breast Cancer Res Treat | 2003 | https://conductscience.org/library/papers/12602919 | PubMed |
| 15 | 18465341 | The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D. | Acta Oncol | 2008 | https://conductscience.org/library/papers/18465341 | PubMed |
| 16 | 3299059 | Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. | Mol Cell Biol | 1987 | https://conductscience.org/library/papers/3299059 | PubMed |
| 17 | 16166438 | Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. | Clin Cancer Res | 2005 | https://conductscience.org/library/papers/16166438 | PubMed |
| 18 | 18768436 | Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. | J Clin Oncol | 2008 | https://conductscience.org/library/papers/18768436 | PubMed |
| 19 | 16258083 | Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. | J Clin Oncol | 2005 | https://conductscience.org/library/papers/16258083 | PubMed |
| 20 | 7779724 | CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study). | Br J Cancer | 1995 | https://conductscience.org/library/papers/7779724 | PubMed |
Cited by95
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 172 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42941759 | TOP2A Overexpression as a Prognostic Biomarker in High-Grade Meningioma: An Integrated Single-Cell and Bulk Transcriptomic Study. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42941759 | PubMed |
| 42465750 | Targeting the E2F6-TOP2A-DKK1 axis: a novel therapeutic strategy for EMT-driven hepatocellular carcinoma progression. | Front Immunol | 2026 | https://conductscience.org/library/papers/42465750 | PubMed |
| 42106529 | Identification of biomarkers associated with diagnosis of gastroesophageal junction adenocarcinoma and their correlation with immune infiltration. | Discov Oncol | 2026 | https://conductscience.org/library/papers/42106529 | PubMed |
| 42098228 | Expression of HER2 in the eye and the potential for on-target side effects with antibody-drug conjugates. | Sci Rep | 2026 | https://conductscience.org/library/papers/42098228 | PubMed |
| 41648744 | Integration of genomic aberrations to predict clinical outcomes for patients with gastroesophageal adenocarcinoma receiving neoadjuvant chemotherapy. | ESMO Gastrointest Oncol | 2024 | https://conductscience.org/library/papers/41648744 | PubMed |
| 41153808 | Novel Cross-Cancer Hub Genes in Doxorubicin Resistance Identified by Transcriptional Mapping. | Biomedicines | 2025 | https://conductscience.org/library/papers/41153808 | PubMed |
| 40831931 | A four-gene signature identified by integrated transcriptomic analysis for differential diagnosis and prognosis of uterine smooth muscle tumors. | Front Oncol | 2025 | https://conductscience.org/library/papers/40831931 | PubMed |
| 40123578 | Targeting DNA Topoisomerase IIα in Retinoblastoma: Implications in EMT and Therapeutic Strategies. | Biologics | 2025 | https://conductscience.org/library/papers/40123578 | PubMed |
| 39670307 | Advances in research on malignant tumors and targeted agents for TOP2A (Review). | Mol Med Rep | 2025 | https://conductscience.org/library/papers/39670307 | PubMed |
| 39063165 | Bicalutamide Enhances Conventional Chemotherapy in In Vitro and In Vivo Assays Using Human and Canine Inflammatory Mammary Cancer Cell Lines. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39063165 | PubMed |
| 38453781 | Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. | Breast Cancer Res Treat | 2024 | https://conductscience.org/library/papers/38453781 | PubMed |
| 37746544 | Evaluation of Expression Level of miR-3135b-5p in Blood Samples of Breast Cancer Patients Experiencing Chemotherapy-Induced Cardiotoxicity. | Indian J Clin Biochem | 2023 | https://conductscience.org/library/papers/37746544 | PubMed |
| 37176164 | Recent Developments in Combination Chemotherapy for Colorectal and Breast Cancers with Topoisomerase Inhibitors. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37176164 | PubMed |
| 36698078 | A clinicopathological study and survival analysis of 99 breast cancers with HER2/CEP17 ratio ≥ 2.0 and an average HER2 copy number < 4.0 per cell in China. | BMC Cancer | 2023 | https://conductscience.org/library/papers/36698078 | PubMed |
| 36551262 | Comprehensive Analysis of Transcriptomics and Genetic Alterations Identifies Potential Mechanisms Underlying Anthracycline Therapy Resistance in Breast Cancer. | Biomolecules | 2022 | https://conductscience.org/library/papers/36551262 | PubMed |
| 36428728 | Association between CD8+ Tumor Infiltrating Lymphocytes and the Clinical Outcome of Patients with Operable Breast Cancer Treated with Adjuvant Dose-Dense Chemotherapy-A 10 Year Follow-Up Report of a Hellenic Cooperative Oncology Group Observational Study. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36428728 | PubMed |
| 36358657 | A Multi-Center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix® PC1 System. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36358657 | PubMed |
| 35805084 | Mitochondria and Doxorubicin-Induced Cardiomyopathy: A Complex Interplay. | Cells | 2022 | https://conductscience.org/library/papers/35805084 | PubMed |
| 35792986 | Genomic copy number alterations as biomarkers for triple negative pregnancy-associated breast cancer. | Cell Oncol (Dordr) | 2022 | https://conductscience.org/library/papers/35792986 | PubMed |
| 35565244 | Oral Etoposide and Trastuzumab Use for HER2-Positive Metastatic Breast Cancer: A Retrospective Study from the Institut Curie Hospitals. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35565244 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| TOP2A | 7153 | PubTator's text mining | https://conductscience.org/library/genes/7153 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/21189395
GET https://conductscience.org/api/papers/v1/21189395/references?page=2